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Abstract
Background
The menstrual cycle is regulated by reproductive hormones such as estrogen which has
been implicated in the pathogenesis of hypertension and is associated with obesity. How-
ever, to date there has scant study of hypertension in relation to menstrual characteristics
and abnormalities. We hypothesize that adverse menstrual characteristics are associated
with an increase the prevalence of hypertension and that this relationship is exacerbated by
obesity.
Methods
Our study leverages 178,205 healthy female participants (mean age = 29) in a population-
based cross-sectional study in Tianjin, China. Menstrual characteristics including menstrual
cycle length and regularity, menstrual bleeding length, menstrual blood loss and dysmenor-
rhea were assessed by self-reported questionnaires, and hypertension was diagnosed by
physician. Multiple logistic regression models were used to assess the relationships
between menstrual characteristics and hypertension.
Results
Normal length menstrual cycle (OR = 1.21, 95% CI: 1.03–1.41), oligomenorrhea (OR =
1.54, 95% CI: 1.12–2.07), irregular cycle (OR = 1.54, 95% CI: 1.22–1.93), and light men-
strual blood loss (OR = 1.36, 95% CI: 1.06–1.72) were associated with hypertension among
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women who are overweight or obese, but not among women who are normal weight. Longer
menstrual bleeding duration (OR = 1.44, 95% CI: 1.24–1.67) and dysmenorrhea were asso-
ciated with increased prevalence of hypertension (OR = 1.20, 95% CI: 1.14–1.41) in all
young women.
Conclusions
The prevalence of hypertension is higher among women with menstrual abnormalities, and
this association is modified by overweight and obesity.
Introduction
The menstrual cycle is regulated by many different reproductive hormones that are released by
the hypothalamus and the pituitary gland [1]. Menstrual abnormalities include painful cramps
(dysmenorrhea), heavy bleeding (menorrhagia), absence of menstruation (amenorrhea), light
or infrequent menstruation (oligomenorrhea) and premenstrual syndrome (PMS)[2–8]. These
can be caused by a range of factors, including hormonal imbalances, genetic factors, infection,
stress, and clotting disorders [9, 10], and are associated with complications such as anemia,
osteoporosis, and in severe cases, infertility [11]. Abnormal menstrual patterns caused by
altered hormonal balance may mediate the risk of hypertension. For example, estrogen can
play a role in protecting against cardiovascular diseases (CVDs) including hypertension by
vasodilator function [12, 13], while androgens may increase blood pressure and thereby con-
tribute to the pathogenesis of hypertension [14, 15]. Furthermore, many of the known risk fac-
tors for menstrual abnormalities, such as weight, age, smoking, family history, pregnancy
history and stress [16], are also risk factors for the development of hypertension. However, to
date there are few studies that have reported the prevalence of hypertension in women with
menstrual abnormalities.
Obesity is associated with increased risk of hypertension, accounting for more than two-
thirds of essential hypertension [17]. More than one-third of adults in the world are over-
weight or obese, and therefore it represents a threat to global health [18]. Furthermore, obesity
frequently displays synergy with exposures upon health outcomes, including hypertension.
Therefore, obesity could exacerbate the effect of adverse menstrual characteristics to increase
the prevalence of hypertension. Hence, here we investigated the association between menstrual
abnormalities, including cycle length, regularity, bleeding duration, blood loss and dysmenor-
rhea, and the prevalence of hypertension (normal, elevated, Stage 1 and Stage 2) in young
adult women (n = 178,205). We then examined how obesity modifies the effect of menstrual
abnormalities upon the prevalence of hypertension. We report that overweight/obesity ampli-
fied the effect of the association between menstrual abnormalities and hypertension in young
adults.
Materials and methods
Participants
Project Environmental and LifEstyle FActors iN metabolic health throughout life-course Tra-
jectories (ELEFANT) incorporates three population-based studies: Baby (mean age 0), Young
(mean age 29) and Elderly ELEFANT (mean age 69). All participants resided in Tianjin (area:
11760 km2), China at the time of recruitment. In this study, we utilized the Young ELEFANT
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PLOS ONE | https://doi.org/10.1371/journal.pone.0207929 November 28, 2018 2 / 15
then transferred to the Institutional Review Board
of Tianjin Medical University for consideration.
Funding: This work was supported in part by
National Natural Science Foundation of China
(Grant numbers 81602827 to LG and 41601548 to
PL). The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: CVD, Cardiovascular disease; SBP,
systolic blood pressure; DBP, diastolic blood
pressure; Cis, confidence intervals; PMS,
premenstrual syndrome; ELEFANT, Environmental
and LifEstyle FActors iN metabolic health
throughout life-course Trajectories; BP, Blood
pressure; ORs, odds ratios.
cohort, using cross-sectional data from 2011–2014. The total number of participants within
Young ELEFANT is 356,410 (50% women). Basic demographic and clinical characteristics
were measured during routine checkups. The participants also completed questionnaires
which assessed lifestyles such as smoking, alcohol consumption, psychological stress, educa-
tion level, occupation, reproductive characteristics (age at menarche, menstrual cycle length,
menstrual bleeding duration, dysmenorrheal and parity), history of disease, familial history of
disease, medication use, and others. The protocol of this study was approved by the Institu-
tional Review Board of the Tianjin Medical University before the experiment was started and
participants gave written informed consent prior to participation in the study.
Study design
The Young ELEFANT cohort contains a total of 178,205 female participants (Fig 1). We
excluded participants with a history of cancer, heart disease, birth defect and participants aged
>40 years in order to improve homogeneity of the study population and avoid the instability
of menstrual characteristics during pre-menopause. Participants with missing data were also
excluded. Following these exclusions, 168,870 participants were included in the final analysis.
Furthermore, considering that oral contraception might affect menstrual characteristics, a sen-
sitivity analysis was performed in participants not using the oral contraceptive (n = 167,643).
Assessment of hypertension
After 5 to 10 minutes of rest, individual blood pressure was measured twice in the upper left
arm in a seated position using an automatic device (HBP-9021J, Omron, Japan). The blood
pressure value was defined as the mean of the two measurements. Hypertension was diagnosed
according to the 2017 High Blood Pressure Clinical Practice Guideline [19] and thereby cate-
gorized into normal blood pressure (systolic blood pressure (SBP)<120 mm Hg and diastolic
blood pressure (DBP)<80 mm Hg), elevated (SBP 120–129 mm Hg and DBP<80 mm Hg),
hypertension Stage 1 (SBP 130–139 mm Hg or DBP 80–89 mm Hg), and hypertension Stage 2
(SBP�140 mm Hg or DBP�90 mm Hg).
Assessment of menstrual characteristics
Women reported their usual menstrual cycle characteristics including cycle length, bleeding
duration, blood loss, and having dysmenorrhea in the aforementioned questionnaires. The
participants reported the upper and lower limit of cycle length and bleeding duration. Irregu-
lar cycles were defined as a difference of 7 days or more in cycle length between the upper and
lower limits [20]. Polymenorrhea was defined with average cycle of 21 days and oligomenor-
rhea was having average cycle of 36 days and longer, in line with studies elsewhere [21]. Nor-
mal cycle was dichotomized into short normal (>21 and�29 days) and long normal (>29 and
�35 days), as 29 days was the median in the cohort. The normal menstrual bleeding duration
ranged between 3 to 7 days [21]. A menstrual pictogram was provided for all participants to
evaluate their usual menstrual blood loss [5, 22], with the amount of menstrual blood loss esti-
mated using the images and self-reported usual numbers of sanitary napkins or tampons used,
which was categorized as light (<20 mL), medium (20-80mL), and heavy (>80 mL). Dysme-
norrhea was defined as crampy and spasmodic pain in lower abdomen radiating to the back
and thighs, which begins just before or as menstrual bleeding begins, and gradually diminishes
over 1 to 3 days [23].
Menstrual abnormalities and hypertension
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Assessment of other variables
Data on age at enrollment, education, occupation, lifestyles, family history of disease, repro-
ductive characteristics and medication usage were collected in the interview utilizing a struc-
tured questionnaire. Education was calculated by the maximum years of formal schooling and
classified into three categories of�9, 10~15 and�16 years. Occupation was categorized as
manual work, non-manual work or unemployment. According to their registered permanent
Fig 1. Study design and participant flow chart for the present study.
https://doi.org/10.1371/journal.pone.0207929.g001
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residence, the region in which the participants lived was dichotomized into rural and urban.
Cigarette smoking (current smokers vs. former or non-smokers), passive smoking (current
passive smokers vs. former or non- passive smokers) and alcohol consumption (current drink-
ers vs. former or non-drinkers) were dichotomized. Psychological stress, including work-
related, social and economic stress, was also dichotomized. Parity was dichotomized as one or
fewer vs. two or more. The use of oral contraceptive pill was grouped as current, former user
and non-user. Family history of hypertension was dichotomized to ‘yes’ or ‘no’. According a
standard protocol, we measured anthropometric measures of each participant, and body mass
index (BMI) was calculated as weight/height2 (kg/m2). According to clinical standards in
China, overweight was defined as BMI between 24.0 kg/m2 and 28.0 kg/m2 and obesity was as
BMI� 28.0 kg/m2 [24].
Statistical analysis
Characteristics between normotension and hypertension were analyzed with t tests for normal
distributive continuous variables, Wilcoxon test for skewed distributive variables and Chi-
square tests or Fisher test for categorical variables. Logistic regression analyses were performed
to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for hypertension in rela-
tion to menstrual characteristics including menstrual cycle (reference group: short normal
cycle, of 21–29 days), menstrual bleeding duration (reference group: 3–7 days), menstrual
blood loss (reference group: medium) and dysmenorrhea. To understand whether potential
confounders could affect the ORs, we adjusted our models for age, BMI, fasting blood glucose
level (FBG), smoking status, passive smoking status, alcohol consumption, education, occupa-
tion, region, parity, oral contraceptive use, age at menarche and family history of hypertension.
The associations between BMI groups were analyzed by healthy weight (18.5�BMI < 24) or
overweight and obesity (BMI� 24). We performed the multiplicative interactions between
menstrual characteristics and BMI groups inputting the product interaction terms in the logis-
tic regression model adjusting the potential confounders using the likelihood ratio test. Sensi-
tivity analyses were performed with participants not using oral contraception. All statistical
analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA). A two-tailed p
value of less than 0.05 was considered to be statistically significant.
Results
A total of 168,870 young women were analyzed in this cross-sectional study. Among the
young adult women, 6.05% had elevated blood pressure, 30.46% Stage 1 hypertension, and
3.28% Stage 2 hypertension (Table 1). The mean age of the participants was 28 in normoten-
sive group and 30 in Stage 2 hypertension (Table 1).
Menstrual abnormalities including menstrual cycle length, bleeding duration, blood loss
and dysmenorrhea were examined with the prevalence of hypertension. The multivariable
adjusted models showed that the odds of having Stage 2 hypertension were higher in women
with longer menstrual cycle length (>29 and�35 days: OR 1.14, 95% CI 1.07–1.22; and>35
days: OR 1.50, 95% CI 1.29–1.74) and irregular cycle (OR 1.29, 95% CI 1.26–1.43). The ORs of
Stage 2 hypertension were also higher with menstrual bleeding duration of less than 3 days
(1.26, 95% CI 1.02–1.54) or longer than 7 days (1.58, 95% CI 1.44–1.72). Young women with
menstrual blood loss of<20 mL or >80mL had significantly higher ORs for Stage 2 hyperten-
sion (1.27, 95% CI 1.13–1.41 and 1.41, 95% CI 1.25–1.59, respectively). Young women with
dysmenorrhea showed significantly higher OR for Stage 2 hypertension than women without
it (1.32, 95% CI 1.25–1.40) (Fig 2). The ORs for elevated blood pressure and Stage 1 hyperten-
sion did not increase with menstrual abnormalities, except menstrual blood loss (1.20, 95% CI
Menstrual abnormalities and hypertension
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1.08–1.33 for elevated and 1.11, 95% CI 1.05–1.17 for Stage 1). The model was adjusted for age
at enrollment, smoking, passive smoking, alcohol consumption, BMI, FBG, education,
Table 1. Basic characteristics of the study population.
Variables Normotension Elevated Stage 1 Stage 2 P�
Total, n (%) 101671 (60.21%) 10220 (6.05%) 51440 (30.46%) 5539 (3.28%)
Age, years (SD) 28 (4.14) 29 (4.28) 28 (4.39) 30 (4.51) <0.0001
BMI, kg/m2 (SD) 22 (3.94) 23 (4.52) 23 (3.95) 26 (4.78) <0.0001
Overweight, n (%) 15492 (15.24%) 2163 (21.16%) 11892 (23.12%) 1707 (30.82%) <0.0001
Obesity, n (%) 4500 (4.43%) 851 (8.33%) 4970 (9.66%) 1526 (27.55%) <0.0001
SBP, mmHg (SD) 105.91 (6.28) 121.03 (2.15) 119.68 (5.56) 137.75 (14.54) <0.0001
DBP, mmHg (SD) 67.26 (5.23) 71.45 (4.13) 80.32 (2.08) 91.84 (9.11) <0.0001
FBG, mmol/L(SD) 5.00 (0.95) 5.11 (1.32) 5.08 (1.23) 5.53 (1.91) <0.0001
Drinking, n (%) 5984 (5.90%) 615 (6.03%) 2682 (5.23%) 458 (8.30%) <0.0001
Smoking, n (%) 1183 (1.17%) 157 (1.54%) 550 (1.07%) 118 (2.14%) <0.0001
Passive smoking, n (%) 21890 (21.57%) 2469 (24.19%) 11301 (22.01%) 1715(31.02%) <0.0001
Education
�9 years, n (%) 43971 (43.32%) 4820 (47.31%) 25327 (49.31%) 2812 (51.00%) <0.0001
10~15 years, n (%) 17536 (17.29%) 1546 (15.17%) 7997 (15.57%) 867 (15.72%)
�16 years, n (%) 39965 (39.40%) 3823 (37.52%) 18035 (35.12%) 1835 (33.28%)
Occupation
Manual work, n (%) 74328 (73.42%) 7594 (74.83%) 39972 (78.00%) 4122 (74.82%) <0.0001
Non-manual work, n (%) 22404 (22.13%) 2085 (20.54%) 9214 (17.98%) 1052 (19.10%)
Unemployment, n (%) 4507 (4.45%) 470 (4.63%) 2062 (4.02%) 335 (6.08%)
Region
Rural, n (%) 73152 (71.94%) 7427 (72.67%) 40015 (77.79%) 3927 (70.90%) <0.0001
Urban, n (%) 28519 (28.06%) 2793 (27.33%) 11425 (22.21%) 1612 (29.10%)
Psychological stress, n (%) 21876 (21.58%) 2458 (24.08%) 10436 (20.33%) 1655 (29.94%) <0.0001
Oral contraception use, n (%) 685 (0.67%) 115 (1.13%) 368 (0.72%) 59 (1.07%) <0.0001
Parity
None, n (%) 54922 (54.06%) 5034 (49.29%) 26390 (51.33%) 2495 (45.07%) <0.0001
�1 times, n (%) 46666 (45.94%) 5180 (50.71%) 25024 (48.67%) 3041 (54.93%)
Age at menarche, years (SD) 13.85 (1.35) 13.87 (1.40) 13.88 (1.35) 13.84 (1.62) 0.0082
Menstrual cycle, days (SD) 29.91 (5.24) 29.96 (7.14) 29.89 (5.84) 30.60 (7.23) <0.0001
Menstrual cycle
Regular cycle, n (%) 94788 (93.26%) 9664 (94.56%) 48826 (94.92%) 5081 (91.73%) <0.0001
Irregular cycle, n (%) 6883 (6.74%) 556 (5.44%) 2614 (5.08%) 458 (8.27%)
Menstrual bleeding duration, days (SD) 5.42 (1.21) 5.46 (1.42) 5.22 (1.21) 5.62 (1.26) <0.0001
Menstrual blood loss
<20 mL, n (%) 4770 (4.69%) 449 (4.39%) 2252 (4.38%) 410 (7.40%) 0.0010
20-80mL, n (%) 93414 (91.88%) 9330 (91.29%) 47145 (91.65%) 4770 (86.12%)
>80mL, n (%) 3486 (3.43%) 441 (4.32%) 2043 (3.97%) 359 (6.48%)
Dysmenorrhea, n (%) 42124 (41.44%) 3769 (36.88%) 16788 (32.64%) 2489 (44.94%)
Family history of hypertension, n (%) 169 (0.17%) 33 (0.32%) 31 (0.06%) 7 (0.13%) <0.0001
Continuous variables were expressed by means (SD) and categorical variables were expressed by number (%). BMI: body mass index; SBP: systolic blood pressure; DBP:
diastolic blood pressure, T2DM: type 2 diabetes mellitus.
�Comparison between normotension, elevated blood pressure, stage 1 and stage 2 hypertension: p-value from ANOVA, chi-square test or fisher test.
Numbers of subjects with missing value were 306 for passive smoking, 319 for smoke, 483 for drinking, 367 for education, 725 for occupation, 410 for psychological
stress, 118 for parity, and 89 for age at menarche.
https://doi.org/10.1371/journal.pone.0207929.t001
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occupation, region, psychological stress, parity, oral contraceptive use, age at menarche and
family history of hypertension (Table 2).
The associations between menstrual characteristics including menstrual cycle length, bleed-
ing duration and blood loss and the prevalence of hypertension were different by BMI group
(18.5�BMI< 24, healthy weight vs BMI�24, overweight and obese) (Tables 3 and 4, related P
for interaction is <0.05). Among healthy weight individuals, the ORs for elevated blood pres-
sure were higher with menstrual cycle length of>29d and�35d (1.05, 95% CI 1.00–1.12),
menstrual bleeding duration of> 7days (1.12, 95% CI 1.02–1.23), and menstrual blood loss of
>80mL (1.25, 95% CI 1.09–1.42). The ORs for Stage 2 were higher with menstrual bleeding
duration of> 7days (1.36, 95% CI 1.16–1.59) and dysmenorrhea (1.45, 95% CI 1.32–1.59) (Fig
3 and Table 3). Participants with underweight are shown in S1 Table.
However, among overweight and obese women, the ORs of Stage 2 hypertension were sig-
nificantly higher in participants by most of the menstrual abnormalities, including menstrual
cycle length of 29-35days and>35days, irregular cycle, menstrual bleeding duration of
>7days, menstrual blood loss of>80 mL and dysmenorrhea (Fig 3 and Table 4). In women
with menstrual bleeding duration of>7days or menstrual blood loss of>80 mL, significantly
higher ORs were present for Stage 1 hypertension (Table 4).
In the sensitivity analyses after excluding the women who reported using the oral con-
traceptive pill, we found similar results as when they were included (S2 Table), including when
categorized by BMI (S3 Table).
Fig 2. The ORs with 95% CIs for Stage 2 hypertension by menstrual abnormalities. ORs were adjusted for age at enrollment, smoking,
passive smoking, drinking, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, and age at menarche.
https://doi.org/10.1371/journal.pone.0207929.g002
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Discussion
The present study assessed the relationship between menstrual abnormalities with hyperten-
sion by blood pressure and the role of obesity in this association in young Chinese women. We
Table 2. The ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities.
Total n n OR (95%CI)� Pinteraction
Elevated (n = 10220) Menstrual cycle length �21d 369 21 0.94 (0.58, 1.46) 0.8837
>21d and�29d 115772 6960 1.00 (ref)
>29d and�35d 38359 2463 1.06 (1.01, 1.12) 0.5049
>35d 3890 220 0.91 (0.79, 1.05) 0.6308
Irregular cycle 10480 556 0.82 (0.75, 0.90) 0.2790
Menstrual bleeding duration <3d 2040 134 1.01 (0.84, 1.21) 0.1910
�3d and�7d 153708 9221 1.00 (ref)
>7d 13122 865 1.07 (0.99, 1.16) 0.8925
Menstrual blood loss <20 mL 7883 449 0.87 (0.78, 0.96) 0.9365
20-80mL 154656 9330 1.00 (ref)
>80mL 6331 441 1.20 (1.08, 1.33) 0.9468
Dysmenorrhea No 103689 6451 1.00 (ref)
Yes 65181 3769 0.83 (0.79, 0.87) 0.5372
Stage 1 (n = 52440) Menstrual cycle length �21d 369 123 1.12 (0.89, 1.40) 0.4714
>21d and�29d 115772 36392 1.00 (ref)
>29d and�35d 38359 11174 0.94 (0.92, 0.97) 0.0420
>35d 3890 1137 0.97 (0.90, 1.04) 0.0206
Irregular cycle 10480 2614 0.74 (0.70, 0.77) 0.0225
Menstrual bleeding duration <3d 2040 581 0.90 (0.81, 1.00) 0.3369
�3d and�7d 153708 47278 1.00 (ref)
>7d 13122 3581 0.95 (0.91, 1.01) 0.0078
Menstrual blood loss <20 mL 7883 2252 0.94 (0.90, 1.00) 0.5471
20-80mL 154656 47145 1.00 (ref)
>80mL 6331 2043 1.11 (1.05, 1.17) 0.1325
Dysmenorrhea No 103689 35652 1.00 (ref)
Yes 65181 16788 0.73 (0.71, 0.74) 0.6994
Stage 2 (n = 5539) Menstrual cycle length �21d 369 22 1.30 (0.76, 2.02) 0.3225
>21d and�29d 115772 3477 1.00 (ref)
>29d and�35d 38359 1376 1.14 (1.07, 1.22) 0.5974
>35d 3890 212 1.50 (1.29, 1.74) 0.0268
Irregular cycle 10480 458 1.29 (1.16, 1.43) 0.0946
Menstrual bleeding duration <3d 2040 115 1.26 (1.02, 1.54) 0.4944
�3d and�7d 153708 4698 1.00 (ref)
>7d 13122 726 1.58 (1.44, 1.72) <0.0001
Menstrual blood loss <20 mL 7883 410 1.27 (1.13, 1.41) 0.0217
20-80mL 154656 4770 1.00 (ref)
>80mL 6331 359 1.41 (1.25, 1.59) 0.6142
Dysmenorrhea No 103689 3050 1.00 (ref)
Yes 65181 2489 1.32 (1.25, 1.40) 0.2806
�Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age
at menarche, family history of hypertension.
Pinteraction is the p value for interaction between BMI and menstrual characteristics.
https://doi.org/10.1371/journal.pone.0207929.t002
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found that longer menstrual cycle (>29 days), irregular cycle, light (<20mL) and heavy
(>80mL) menstrual blood loss were associated with Stage 2 hypertension among overweight
and obese women, but not in normal weight women (BMI�24). Longer duration of menstrual
bleeding (>7days) and dysmenorrhea were associated with Stage 2 hypertension irrespective
of BMI. Our results suggest that BMI may modify the association between menstrual abnor-
malities and hypertension in young women.
Table 3. The ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities among young women in who are healthy weight.
Healthy weight (18.5�BMI< 24, n = 112149)
Elevated (n = 6551) Stage 1 (n = 31395) Stage 2 (n = 2183)
Total n n OR (95% CI)� n OR (95% CI)� n OR (95% CI)�
Menstrual cycle length �21d 214 15 1.27 (0.71, 2.11) 75 1.32 (0.98, 1.76) 2 0.41 (0.07, 1.29)
>21d and�29d 78605 4551 1.00 (ref) 22958 1.00 (ref) 1589 1.00 (ref)
>29d and�35d 24882 1564 1.05 (1.00, 1.12) 6525 0.91 (0.88, 0.94) 446 0.95 (0.85, 1.06)
>35d 2218 119 0.85 (0.70, 1.03) 559 0.91 (0.82, 1.00) 48 1.21 (0.82, 1.50)
Irregular cycle 6230 302 0.75 (0.66, 0.84) 1278 0.67 (0.62, 0.71) 98 0.86 (0.70, 1.06)
Menstrual bleeding duration <3d 1237 78 0.98 (0.77, 1.24) 310 0.88 (0.77, 1.01) 36 1.33 (0.93, 1.85)
�3d and�7d 102771 5917 1.00 (ref) 29095 1.00 (ref) 1943 1.00 (ref)
>7d 8141 556 1.12 (1.02, 1.23) 1990 0.90 (0.85, 0.95) 204 1.36 (1.16, 1.59)
Menstrual blood loss <20 mL 4791 274 0.88 (0.77, 1.00) 1220 0.91 (0.85, 0.98) 118 1.05 (0.86, 1.27)
20-80mL 103670 6008 1.00 (ref) 29150 1.00 (ref) 1983 1.00 (ref)
>80mL 3688 269 1.25 (1.09, 1.42) 1025 1.01 (0.94, 1.10) 82 1.08 (0.85, 1.36)
Dysmenorrhea No 68791 4085 1.00 (ref) 21352 1.00 (ref) 1198 1.00 (ref)
Yes 43358 2466 0.85 (0.80, 0.90) 10043 0.69 (0.67, 0.71) 985 1.45 (1.32, 1.59)
�Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age
at menarche, family history of hypertension.
https://doi.org/10.1371/journal.pone.0207929.t003
Table 4. ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities among young women who are overweight and obese.
Overweight and obese (BMI�24, n = 43109)
Elevated (n = 10220) Stage 1 (n = 52440) Stage 2 (n = 5539)
Total n n OR (95% CI)� n OR (95% CI)� n OR (95% CI)�
Menstrual cycle length �21d 114 5 0.62 (0.21, 1.41) 40 0.95 (0.62, 1.44) 19 1.76 (0.98, 2.98)
>21d and�29d 28465 1988 1.00 (ref) 11243 1.00 (ref) 1804 1.00 (ref)
>29d and�35d 9862 714 1.05 (0.96, 1.16) 3863 1.04 (0.99, 1.09) 894 1.28 (1.17, 1.40)
>35d 1315 86 0.97 (0.76, 1.23) 519 1.11 (0.98, 1.26) 162 1.61 (1.34, 1.93)
Irregular cycle 3353 221 0.93 (0.80, 1.08) 1197 0.91 (0.84, 0.98) 354 1.50 (1.32, 1.70)
Menstrual bleeding duration <3d 658 47 1.00 (0.72, 1.36) 241 0.92 (0.77, 1.09) 76 1.19 (0.91, 1.53)
�3d and�7d 39038 2729 1.00 (ref) 15325 1.00 (ref) 2656 1.00 (ref)
>7d 3413 238 1.06 (0.91, 1.23) 1296 1.08 (1.00, 1.16) 501 1.78 (1.59, 1.99)
Menstrual blood loss <20 mL 2294 145 0.88 (0.73, 1.05) 868 1.01 (0.92, 1.11) 281 1.40 (1.22, 1.61)
20-80mL 38682 2721 1.00 (ref) 15093 1.00 (ref) 2678 1.00 (ref)
>80 mL 2133 148 1.15 (0.95, 1.37) 901 1.27 (1.15, 1.40) 274 1.53 (1.33, 1.76)
Dysmenorrhea No 27545 1975 1.00 (ref) 11328 1.00 (ref) 1787 1.00 (ref)
Yes 15564 1039 0.80 (0.74, 0.88) 5534 0.78 (0.75, 0.82) 1446 1.27 (1.17, 1.37)
�Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age
at menarche, and family history of hypertension.
https://doi.org/10.1371/journal.pone.0207929.t004
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Fig 3. The ORs with 95% CIs for Stage 2 hypertension by menstrual abnormalities in different BMI categories. ORs were adjusted for age at
enrollment, smoking, passive smoking, drinking, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, and age at
menarche.
https://doi.org/10.1371/journal.pone.0207929.g003
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There have been conflicting results from studies investigating the association between men-
strual cycle characteristics and hypertension. Irregular menstrual cycles and oligomenorrhea
have been reported to be potential markers of CVD risk, including coronary heart disease, in a
cohort study of European women, and were also associated with arterial hypertension in a ret-
rospective case-control study of 414 postmenopausal Brazilian women [25, 26]. Longer men-
strual cycle length has also been reported to be associated with CVD risk factors such as blood
lipid levels and DBP [27]. However, a retrospective case-control study of Chinese women
reported no association between menstrual cycle length and hypertension among postmeno-
pausal women [28]. We speculate that these conflicting results may in part be the product of
the retrospective studies being conducted in postmenopausal women, thereby potentially
being affected by menstrual irregularities during the pre-menopause. Furthermore, obesity has
been shown to be significantly associated with having an irregular menstrual cycle. To the best
of our knowledge, our study is the largest to examine the association between menstrual cycle
characteristics and the prevalence of hypertension, and the first to examine the modifying
effect of obesity. We report that oligomenorrhea (36 days and longer), normal prolonged men-
strual cycle (29–35 days) and irregular menstrual cycle were each associated with the preva-
lence of Stage 2 hypertension in young obese women but not in healthy weight women.
The underlying mechanism explaining the relationship between menstrual cycle length and
hypertension in obese women is unclear. Lower estrogen levels can lead to a longer or irregular
menstrual cycle in women [7, 17]. In addition, these can be the product of inadequate follicular
development leading to prolonging of the follicular phase of the cycle, which in itself is often
associated with lower average estrogen concentrations [7, 17, 29, 30]. It is known that estradiol
(E2) can execute vasodilator function by augmentation of the beta-adrenergic receptor, and
reducing oxidative stress [12, 13]. Thus, we speculate that decreased estrogen levels may
explain the mechanism underlying the association between irregular or prolonged menstrual
cycle length and hypertension. In addition, obese women have much greater amplitudes of
changes in sex hormone levels across the menstrual cycle to maintain hormonal homeostasis
compared to normal weight women [31]. Adiposity itself can contribute to endothelial or vaso-
dilator dysfunction by production of reactive oxygen species (ROS) and inflammation media-
tors, similar to lower estrogen levels [32]. Indeed, lower estrogen levels together with increased
BMI could bring out apparent impairment of vascular function such as hypertension. This
may explain why the association between menstrual cycle and hypertension was only observed
among obesity or overweight women.
There have been few previous reports on menstrual bleeding patterns, such as duration and
blood loss, with hypertension and CVD. Just as with cycle characteristics, we observed light
menstrual blood loss to be associated with increased odds of hypertension only among young
women who are overweight or obese, and longer menstrual bleeding duration was also associ-
ated with prevalence of hypertension among overweight and obese women. During a normal
menstrual period, estrogen levels reduce a few days before the endometrium thickens [33]. If
the levels of estrogen are reduced abnormally, this slows the endometrial repair period, con-
tributing to longer bleeding duration and relatively lighter blood loss [34]. Moreover, long
bleeding durations are associated with anovulatory cycles which relate to significant reduction
in estradiol level [35]. Therefore, it could be that it is changes in estrogen levels that determine
the increased prevalence of hypertension among young obese women with longer bleeding
duration and lighter blood loss.
Interestingly, dysmenorrhea was shown to be related with increased prevalence of hyper-
tension in both obese and non-obese women in our study. A previous case-control study in
Italy reported that the occurrence of pregnancy-related hypertensive disorders including gesta-
tional hypertension and preeclampsia is influenced by dysmenorrhea [36]. Compared with
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unmenorrheic women, dysmenorrheic women have higher levels of prostaglandins (PGs) in
both endometrial biopsies and circulation, predominantly PGF2a and PGE2 [6], and PGF2a is
known to elevate blood pressure via vasoconstrictor function [35]. The mechanism underlying
this association requires further study.
Several limitations need to be acknowledged. Firstly, information on menstrual cycle were
self-reported by the participants, and therefore recall bias can be present. Although, question-
naire data has been reported to be more accurate among younger participants [25, 37],
response bias has been a key issue in many studies using self-assessed questionnaire data.
Recalibration of response bias has been suggested, however this can cause ‘response-shift bias’
or other types of response bias [38]. Furthermore, this also requires data from multiple mea-
sures and observations [38], which was not available for our analysis. Secondly, due to lack of
long-term follow-up data, we cannot infer causality of hypertension with menstrual character-
istics. Thirdly, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to alleviate the
symptoms of dysmenorrhea, and their chronic usage has been linked with hypertension [39].
However, there is currently no data on NSAID usage within this cohort, and therefore we have
been unable to exclude their confounding effect. Indeed, cross-sectional studies such as ours
are prone to confounding due to the wide range of factors that may be associated with the out-
come. We therefore sought to counter this by adjusting our model for a number of factors
known to be associated with hypertension and for which data was available within the cohort
(e.g. age, BMI, smoking, fasting blood glucose levels, familial history of the disease), but we
cannot exclude the possibility of residual confounding. Finally, the absence of a similarly-sized
population study precluded the validation of our findings in an independent cohort. Nonethe-
less, our study contains several strengths. Firstly, our study has a large sample size and exten-
sive data on menstrual characteristics [26], which we leveraged to comprehensively analyze the
relationship between menstrual characteristics and hypertension. Secondly, the age range of
our participants was narrow, and the relatively young age of the participants meant we were
able to avoid the instability of menstrual characteristics during pre-menopause. Thirdly, we
were able to control for a large number of possible cofounders, including the use of oral
contraceptive.
Conclusions
In conclusion, using a large cross-sectional study based in China, we report that menstrual
abnormities, including menstrual cycle length, blood loss, bleeding duration and dysmenor-
rhea were associated with Stage 2 hypertension, and that this association interacts with over-
weight and obesity. Further investigation is required to confirm our findings in independent
cohorts and elucidate the biological mechanism(s) behind these associations through labora-
tory-based experiments.
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